Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.770
+0.050 (1.06%)
At close: May 19, 2026, 4:00 PM EDT
4.448
-0.322 (-6.76%)
After-hours: May 19, 2026, 7:50 PM EDT
Neuphoria Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Neuphoria Therapeutics stock has a target of 7.00, which predicts a 46.75% increase from the current stock price of 4.77.
Price Target: $7.00 (+46.75%)
Analyst Consensus: Hold
* Price targets were last updated on Sep 11, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Neuphoria Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 15, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $21 → $7 | Strong Buy | Maintains | $21 → $7 | +46.75% | Dec 5, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $18 → $35 | Strong Buy | Maintains | $18 → $35 | +633.75% | Sep 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +340.25% | Aug 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $21 | Strong Buy | Maintains | $8 → $21 | +340.25% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
n/a
from 15.65M
Revenue Next Year
n/a
EPS This Year
-5.68
from -0.23
EPS Next Year
-2.48
from -5.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -4.27 | -2.55 | |
| Avg | -5.68 | -2.48 | |
| Low | -6.93 | -2.38 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.